Effect of resveratrol capsules on knee osteoarthritis symptoms and specific markers of joint breakdown

ISRCTN ISRCTN75392625
DOI https://doi.org/10.1186/ISRCTN75392625
Submission date
21/08/2020
Registration date
09/09/2020
Last edited
06/10/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Osteoarthritis is a condition that causes joints to become painful and stiff. The treatment of knee osteoarthritis still remains a challenge. There is a need not only for effective and safe treatments but also for specific and reliable biomarkers that would help to observe both the progression of the disease and treatment effectiveness. Resveratrol extracted from Polygonum cuspidatum is a natural chemical that is found in grape skin, berries and peanuts. Pre-clinical studies provided evidence on the effectiveness of resveratrol in reducing degenerative articular damage. Recently a clinical study demonstrated the effectiveness of resveratrol as an add-on treatment in alleviating pain and reduction of inflammatory biomarkers. However, there are no clinical trials to date to determine the effectiveness of resveratrol as a treatment in articular disorders particularly in knee osteoarthritis and investigating biomarkers of cartilage breakdown. The aim of this study is to investigate the effects of resveratrol (as an oral capsule) in patients with mild or moderate knee osteoarthritis on the blood levels of specific biomarkers of osteoarthritis and on the evaluation of pain.

Who can participate?
Patients with mild to moderate osteoarthritis

What does the study involve?
The study will involve a 12-week of administration of oral resveratrol (500 mg/day in a single dose). A rescue medication (500 mg of acetaminophen and up to four tablets per day) will be given to the patients for non-tolerated pain they will experience during the study period. Specific biomarkers of osteoarthritis are measured before treatment (at day 0) and after 90 days of treatment.

What are the possible benefits and risks of participating?
The expected benefit of the current study is providing a new approach from a natural source Polygonum cuspidatum for the treatment of knee OA with fewer side effects and more regeneration of the cartilage. No risks are expected unless there might be a non-remarkable result due to the short duration of the study.

Where is the study run from?
Teaching Hospitals of Sulaimani City (particularly Shar Teaching Hospital) (Iraq)

When is the study starting and how long is it expected to run for?
December 2019 to October 2020

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Assistant Professor Dr Bushra Hassan Marouf
bushra.marouf@univsul.edu.iq

Contact information

Dr Bushra Marouf
Public

Sulaimani-Old Campus
Sulaimani
00964
Iraq

ORCiD logoORCID ID 0000-0002-7658-9013
Phone +964 (0)7701562796
Email bushra.marouf@univsul.edu.iq
Dr Bushra Marouf
Scientific

Sulaimani-Old Campus
Sulaimani
00964
Iraq

ORCiD logoORCID ID 0000-0002-7658-9013
Phone +964 (0)7701562796
Email bushra.marouf@univsul.edu.iq

Study information

Study designPilot clinical study of non-randomized non-controlled open-labelled clinical trial
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet No participant information sheet available
Scientific titleA pilot clinical study of the effect of resveratrol on the serum level of Coll 2-1 and Aggrecan biomarkers in patients with knee osteoarthritis; a non-randomized open-labelled clinical trial
Study acronymAPCERCA
Study objectivesStated hypothesis: use of resveratrol (500 mg/day) alone may have a significant effect on the improvement of pain and specific biomarkers (Coll 2-1 and aggrecan) in patients with knee osteoarthritis.
Ethics approval(s)Approved 01/09/2020, Ethical Committee of College of Medicine, University of Sulaimani (Iraq-Kurdistan Region, Sulaimani, Street 27- Zone 209, Iraq; +964 (0)53 3270924; kosar.ali@univsul.edu.iq), ref: 180
Health condition(s) or problem(s) studiedKnee osteoarthritis
InterventionThis is a single-arm non-randomized non-controlled open labelled clinical trial. The study will be a 12-week of administration of oral resveratrol (500 mg/day in a single dose) alone in patients with mild to moderate osteoarthritis. A rescue medication (500 mg of acetaminophen and up to four tablets per day) will be given to the patients for non-tolerated pain they experience during the study period. Resveratrol is a natural phytoalexin that is found in the grape skin, berries and peanuts.
Intervention typeSupplement
Primary outcome measure1. Specific biomarkers of osteoarthritis (Coll 2-1 and Aggrecan) measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer instructions before treatment (at day 0) and after 90 days of treatment.
2. Biomarkers of inflammation including TNF-α, IL-1β, IL-6 (measured using ELISA kit according to the manufacturer instructions) and hsCRP and the complement system (measured by spectrophotometry utilizing ready-made kits and Roche/Hitachi cobas c systems) measured at baseline at Day 0 (pre-treatment) and at day 90 (post treatment)
3. Standard haematological profile (measured utilizing the Swelab Alfa Plus system) and both liver and kidney functions markers (liver and kidney function tests), and lipid profiles measured spectrophotometrically using the clinical chemistry analyzer Cobas c 311 and ready-made kits according to the manufacturer’s recommendations for evaluating safety and tolerability of resveratrol at baseline and at the end of the treatment
Secondary outcome measuresSymptoms of osteoarthritis measured using the adopted scoring systems of visual analogue scale for pain (VAS) and Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline (day 0), 1, 2 and 3 months
Overall study start date01/12/2019
Completion date01/10/2020

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants35-40
Total final enrolment35
Key inclusion criteriaMild to moderate OA at both screening and baseline visits, as defined by the up-to-date revised American College of Rheumatology (ACR) criteria for diagnosis of knee OA
Key exclusion criteria1. Patients with a history of rheumatoid arthritis, gout, severe ischaemic heart disease, heart failure, hepatic failure, renal failure
2. Consumption of non-steroidal anti-inflammatory drugs or corticosteroid drugs within 4 weeks of study, intra-articular injection within 3 months prior to the study recruitment
3. Pregnant or desire to become pregnant, or lactating women
Date of first enrolment10/01/2020
Date of final enrolment10/03/2020

Locations

Countries of recruitment

  • Iraq

Study participating centre

University of Sulaimani
College of Pharmacy with Shar Teaching Hospital
46001 Sulaymaniyah
Kurdistan Region
Sulaimani
00964
Iraq

Sponsor information

University of Sulaimani
University/education

Department of Pharmacology and Toxicology
College of Pharmacy
Sulaimani-Old Campus
Sulaimani
00964
Iraq

Phone +964 (0)7701562796
Email bushra.marouf@univsul.edu.iq

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date14/11/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe researchers plan to publish this work in a high-impact peer-reviewed Journal indexed in Web of Science group (former Clarivate Analytics or Thomson Reuters).
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Assistant Professor Dr Bushra Hassan Marouf (bushra.marouf@univsul.edu.iq).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 11/11/2021 16/11/2021 Yes No
Protocol file 06/10/2022 No No

Additional files

ISRCTN75392625_PROTOCOL.pdf

Editorial Notes

06/10/2022: Uploaded protocol (not peer reviewed).
16/11/2021: Publication reference added.
14/05/2021: The intention to publish date has been changed from 10/10/2020 to 14/11/2021.
07/09/2020: Trial's existence confirmed by the Ethical Committee of College of Medicine, University of Sulaimani.